Voriconazole-induced Severe Hyperkalemia Precipitated by Multiple Drug Interactions

Jae Young Choi1, Seong Geun Cho1, Ki-Seok Jang2, Gheun-Ho Kim1

Departments of 1Internal Medicine and 2Pathology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea

Received: April 13, 2020
Revised: May 15, 2020
Accepted: May 16, 2020
Corresponding Author: Gheun-Ho Kim, MD, PhD
Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, 222-1 Wansimni-ro Seongdong-gu, Seoul 04763, Korea
Tel: +82-2-2290-8318
Fax: +82-2-2298-9183
E-mail: kimgh@hanyang.ac.kr

Voriconazole, a triazole antifungal agent used to treat serious fungal infections, has a pharmacokinetic characteristic of undergoing hepatic metabolism by the cytochrome P450 system. Few cases of hyperkalemia have been reported, which presented only when the serum voriconazole level was exceptionally elevated by drug interactions. Additionally, azole antifungals may interfere with the biosynthesis of adrenal steroids and therefore can predispose patients to aldosterone deficiency. However, it is unclear whether voriconazole itself can induce hypoaldosteronism or hyperkalemia. Here, we report a case of voriconazole-induced hyperkalemia in a patient administered concurrent medications to treat comorbidities. Voriconazole was orally administered for pulmonary aspergillosis, and three episodes of severe hyperkalemia recurred, which improved with emergency treatment. In the first episode, renin-angiotensin-aldosterone system inhibitors were associated. We found that dronedarone might have increased the voriconazole level in the second episode. At that time, severe hypercalcemia was concurrent, which improved with acute hemodialysis and eliminating dronedarone. Finally, severe hyperkalemia recurred without concurrent medications known to interact with voriconazole. Upon switching from voriconazole to itraconazole, the hyperkalemia was resolved. Drug level monitoring is necessary when voriconazole is used. Genetic susceptibility, such as through CYP2C19 polymorphism, may be investigated for patients with adverse reactions to voriconazole.

Key Words: Dronedarone, Drug interactions, Hypercalcemia, Hyperkalemia, Voriconazole

INTRODUCTION

Voriconazole is a triazole antifungal agent used to treat serious fungal infections. It is the first line treatment for invasive aspergillosis, but its therapeutic window is narrow because of unpredictable, nonlinear pharmacokinetics with extensive interpatient and intrapatient variation in serum levels1,2).

Many adverse effects have been described as voriconazole use has increased. Visual disturbances, skin rashes, hallucinations, and hepatotoxicity are well known3), and the increased risk of skin cancer is most concerning4). Electrolyte disturbances such as hyponatremia were rarely reported as adverse reactions to voriconazole5), and it is unclear whether hyperkalemia can be induced by voriconazole alone.

Here, we report the case of voriconazole-associated severe recurrent hyperkalemia, which required emergency treatment including acute hemodialysis. Voriconazole was used to treat pulmonary aspergillosis, and the patient was taking multiple medications for accompanying diseases. Thus, it was probable that drug interactions might occur between medications undergoing hepatic metabolism by the cytochrome P450 system. A causal relationship between voriconazole and hyperkalemia was concluded because hyperkalemia was recurrently provoked by voriconazole
administration and was resolved by discontinuing the offending agent. We discuss a potential mechanism by which hyperkalemia could be induced by drug interactions between voriconazole and cardiovascular medications.

**CASE REPORT**

A 69-year-old male was admitted due to quadriplegic via the emergency room (ER). He had multiple comorbidities: old pulmonary tuberculosis, alcoholic liver cirrhosis, diabetes mellitus, and hypertension. His medications included spironolactone, glimepiride, metformin, amlodipine, and telmisartan. Two weeks earlier, however, he was diagnosed with pulmonary aspergillosis and paroxysmal atrial fibrillation at the outpatient department (OPD). A pulmonologist and a cardiologist prescribed oral voriconazole (200 mg twice a day) and dronedarone (400 mg twice a day), respectively. At this time, serum sodium was 135 mmol/L, potassium was 5.5 mmol/L, and creatinine was 0.91 mg/dL. Figure 1 shows the chest radiographic findings.

At admission, the patient’s blood pressure was 124/52 mmHg, and no focal neurologic deficit was noted on physical examination. Serum sodium was 133 mmol/L, potassium was 8.0 mmol/L, calcium was 9.3 mg/dL, phosphorus was 4.7 mg/dL, and creatinine was 1.57 mg/dL. Electrocardiography (ECG) showed atrial fibrillation and left bundle branch block (Fig. 2A). The severe hyperkalemia appeared to be caused by spironolactone and telmisartan coadministration, and these offending agents were discontinued. In addition, hyperkalemia was antagonized by intravenous calcium gluconate and was corrected by administration of intravenous insulin lispro and calcium polystyrene sulfonate. His proteinuria was persistent, reaching 1,131 mg/d in a 24 h urine collection. Urinalysis showed a specific gravity of 1.007, pH 5.0, albumin 1+, red blood cells 5-9/high power field (HPF), and white blood cells 3-4/HPF. Because monoclonal gamopathy was suggested from serum and urine protein electrophoresis, a kidney biopsy was performed. Light microscopic examination revealed two global scleroses among

---

**Fig. 1. Chest radiologic findings.** Chest PA suggests old tuberculous destroyed lung lesions at upper lobes (A). Chest computed tomography shows ill-defined infiltrations at right middle and lower lung field (B). Serologic test for aspergillus antigen was positive from both serum and bronchoalveolar lavage.

**Fig. 2. Serial electrocardiographic findings.** Atrial fibrillation and left bundle branch block were initially noted (A), bradycardia was aggravated (heart rate 43, B), and then complete atrioventricular block was induced (C). Finally, normal sinus rhythm was recovered (D).
17 glomeruli sampled and showed marked mesangial expansion with mesangial hypercellularity and global thickening of the glomerular capillary walls. Immunofluorescence revealed lambda light chain-restricted glomerular mesangial and linear capillary loop staining (Fig. 3). Electron microscopic evaluation showed vague, fine granular, amorphous deposits in the mesangium and along the peripheral capillary walls. These pathologic findings were compatible with light chain deposition disease. The immunofixation test revealed that heavy and light chains were IgG and \( \lambda \), respectively. However, no osteolytic lesions were found, and the bone marrow was normocellular. Thus, he was discharged without specific treatment while maintaining voriconazole.

Nine days later, the patient was readmitted because of gait disturbance and dysarthria. Brain imaging revealed no acute lesion. Bradyarrhythmia was noted (Fig. 2B), and acute hemodialysis was undertaken to treat both hypercalcemia (11.7 mg/dL) and hyperkalemia (7.5 mmol/L). Urine sodium was 127 mmol/L, potassium was 19 mmol/L, chloride was 125 mmol/L, creatinine was 36 mg/dL, and osmolality was 372 mOsm/kg H₂O. The transtubular potassium gradient (TTKG) was calculated to be 2.02, and arterial blood gas analysis showed a pH of 7.354, pCO₂ 38.5 mmHg, pO₂ 110 mmHg, and HCO₃⁻ 20.9 mmol/L. Results of the following endocrine tests were unremarkable: plasma renin activity, serum aldosterone concentration, intact-PTH, and stimulated cortisol. Vitamin D levels were low, and PTH-related peptide was undetectable. We considered the possibility of voriconazole-induced hyperkalemia; therefore, voriconazole was discontinued. Because the follow-up ECG showed the atrial fibrillation was resolved, dronedarone was discontinued. At discharge, his serum sodium was 135 mmol/L, potassium was 4.1 mmol/L, calcium was 9.5 mg/dL, phosphorus was 3.7 mg/dL, protein was 7.5 g/dL, albumin was 3.1 g/dL, and creatinine was 0.69 mg/dL.

Approximately one month later, the patient was readmitted because of massive hemoptysis and required bronchial artery embolization. The pulmonologist prescribed itraconazole to treat pulmonary aspergillosis. One week later, however, itraconazole was switched to a reduced dose (100 mg twice a day) of voriconazole. In the meantime, antihypertensives were switched to manidipine and propranolol.

Sixteen days after voriconazole had been resumed, serum potassium had increased to 5.7 mmol/L, and one day later, the patient again visited the ER because of chest tightness. His serum sodium was 130 mmol/L, potassium was 8.0 mmol/L, calcium was 8.9 mg/dL, phosphorus was 5.8 mg/dL, and creatinine was 1.63 mg/dL. An ECG suggested complete atrioventricular block (Fig. 2C), and he recovered normal sinus rhythm after acute hemodialysis (Fig. 2D). Once again, voriconazole was replaced with itraconazole (200 mg once a day). Manidipine was discontinued because of the potential drug interaction betweenazole antifungals and calcium channel blockers\(^2\). Plasma renin activity and serum aldosterone were 0.26 (normal, 0.32-1.84) ng/mL/h and 3.0 (normal, 4.2-20.9) ng/dL, respectively. No further electrolyte disturbances were noted during the admission for three weeks, and his final follow-up laboratory findings were: serum sodium 136 mmol/L, potassium 4.4 mmol/L, calcium 9.6 mg/dL, phosphorus 4.4 mg/dL, and creatinine 0.85 mg/dL.
**DISCUSSION**

Figure 4 summarizes the laboratory findings at each episode of acute severe hyperkalemia and medications that we suspect caused hyperkalemia. In the first episode, hyperkalemia was thought to be induced by the combined use of an angiotensin II receptor blocker (telmisartan) and a mineralocorticoid receptor antagonist (spironolactone). During admission, serum potassium was maintained within the normal range while calcium polystyrene sulfonate was orally administered.

We addressed the possibility of voriconazole-induced hyperkalemia in the second episode of acute severe hyperkalemia. Although serum creatinine was elevated to 1.53 mg/dL, the decline in kidney function was not sufficient to explain the hyperkalemia. We had excluded the possibility of hyporeninemic hypoaldosteronism during the previous admission. Voriconazole-associated electrolyte disturbances have been described in only a few reports, and no previous studies found that hyperkalemia was induced by voriconazole alone (Table 1).

Review articles indicate that ketoconazole may induce hyperkalemia by impairing aldosterone secretion. Ketoconazole is an imidazole antifungal agent, while voriconazole is a triazole antifungal. These drugs share a common chemical structure (azole), and azole antifungals may interfere with the biosynthesis of adrenal steroids and therefore can predispose patients to aldosterone deficiency. However, plasma renin activity and serum aldosterone concentration results for our patient were not consistent with primary hypoaldosteronism. Hyporeninemic hypoaldosteronism might be an alternative mechanism for hyperkalemia, but renal pathology in our case was not compatible with diabetic nephropathy.

Triazole antifungals that include fluconazole, itraconazole, posaconazole, and voriconazole are not equivalent in disturbing potassium balance. Unlike fluconazole and voriconazole, itraconazole and posaconazole were reported to show pseudohyperaldosteronism presenting with low-renin hypertension and hypokalemic metabolic alkalosis. A plausible mechanism is inhibition of 11β-hydroxysteroid dehydrogenase 2, with resultant apparent mineralocorticoid...

---

**Table 1. Literature review: voriconazole-associated hyperkalemia**

|                      | Boyd, et al.⁴ | Nazmul, et al.⁶ | Current case |
|----------------------|--------------|----------------|-------------|
| **Voriconazole dosage** | 3 mg/kg i.v. every 12 h | No data available | 200 mg p.o. twice a day |
| **Peak serum K⁺ (mmol/L)** | 7.2 | 8.5 | 8.0 |
| **Interacted drugs** | Amiloride | Tacrolimus | Telmisartan, spironolactone, dronedarone |
| **Other electrolyte disturbance** | Hyponatremia | None reported | Hyponatremia, hypercalcemia |

i.v., intravenous; p.o., per os.
excess\textsuperscript{11}. It is interesting that serum potassium could be increased or decreased depending on the particular triazole antifungal agent.

Another enigma with the second episode is the concurrence of hypercalcemia. However, voriconazole-associated hypercalcemia was reported to occur in patients with acute leukemia\textsuperscript{12,13}. Voriconazole alone was not considered to cause hypercalcemia, but it should exert a synergistic effect on hypercalcemia via drug interactions\textsuperscript{12} or add to an underlying hypercalcemia-prone disease such as fungal granulomas\textsuperscript{13}. Our case had monoclonal gammopathy with light chain deposition disease, but it was not linked to hypercalcemic conditions because no osteolytic lesions were involved.

On the other hand, dronedarone, a class III antiarrhythmic drug, was concurrently used in our patient. Because both dronedarone and voriconazole undergo extensive hepatic metabolism by the cytochrome P450 system, interactions can occur between these two drugs\textsuperscript{1}. Although we did not find any report of dronedarone-associated hypercalcemia, hypercalcemia was described in a patient using amiodarone, the prototype of a class III antiarrhythmic\textsuperscript{14}.

Previous reports of voriconazole-associated hyperkalemia similarly concerned patients with concurrent medications inhibiting cytochrome P450 such as calcineurin inhibitors\textsuperscript{6,7}. Only in the second episode of severe hyperkalemia, were we aware of the potential drug-drug interaction between dronedarone and voriconazole. However, the third episode of severe hyperkalemia was encountered without dronedarone being administered. Thus, we conclude that voriconazole may itself induce hyperkalemia. Voriconazole was replaced with intraconazole after the second episode, but it was resumed by the pulmonologist because of its effectiveness.

In the third episode of severe hyperkalemia, we scrutinized the list of drug-drug interactions with voriconazole. Calcium channel blockers including diltiazem, verapamil, isradipine, and nicardipine may potentially increase the level of voriconazole\textsuperscript{9}. Although manidipine was not listed among calcium channel blockers, we decided not to continue its use. It was unfortunate that therapeutic drug monitoring was unavailable for voriconazole.

Another possibility of raising the voriconazole level is genetic polymorphism of the isoenzyme CYP 2C19\textsuperscript{6,9}. A CYP 2C19 is found in 15 to 20% of Asians\textsuperscript{15}, but we did not obtain this result from our patient. Hepatic dysfunction is another factor that can affect the voriconazole level, but it was not thought to be applicable in our case because his liver function was stable and well-compensated.

It was interesting that each episode of voriconazole-induced hyperkalemia was accompanied by hyponatremia and mild azotemia (Fig. 4). The latter features were rapidly reversible, and it is unclear whether they were caused by voriconazole. Voriconazole is not nephrotoxic, and oral formulation without dosage adjustment can be safely employed in patients with renal failure\textsuperscript{11}. In summary, adverse effects including hyperkalemia, hyponatremia, and nephrotoxicity should be of concern when the trough voriconazole concentration is elevated to a toxic level\textsuperscript{4,7}. It is postulated that pharmacogenetic susceptibility may have a role in voriconazole-induced hyperkalemia.

**Conflict of Interest**

The authors declare no relevant financial interests.

**REFERENCES**

1. Mikulska M, Novelli A, Aversa F, Cesaro S, de Rosa FG, Girmeinia C, et al.: Voriconazole in clinical practice. J Chemother 24:311-327, 2012
2. Malani AN, Kerr LE, Kauffman CA: Voriconazole: How to use this antifungal agent and what to expect. Semin Respir Crit Care Med 36:786-795, 2015
3. Levine MT, Chandrasekar PH: Adverse effects of voriconazole: Over a decade of use. Clin Transplant 30:1377-1386, 2016
4. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW: Adverse reactions to voriconazole. Clin Infect Dis 39:1241-1244, 2004
5. Yu MY, Yeo JH, Park JS, Lee CH, Kim GH: Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients. PLoS One 12(3):e0173542, 2017
6. Nazmul MN, Miles CD, Westphal SG: Severe hyperkalemia complicating voriconazole treatment in a kidney transplant recipient with histoplasmosis: a case report. Transplant Proc 49:2372-2373, 2017
7. Chang HH, Lee NY, Ko WC, Lee HC, Yang YH, Wu CJ, et al.:
Voriconazole inhibition of tacrolimus metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis. Int J Infect Dis 14(4):e348-e350, 2010
8. Nyirenda MJ, Tang JI, Padfield PL, Seckl JR: Hyperkalaemia. BMJ 339:b4114, 2009
9. Palmer BF: Managing hyperkalemia caused by inhibitors of the reninangiotensin-aldosterone system. N Engl J Med 351:585-592, 2004
10. Beck KR, Telisman L, van Koppen CJ, Thompson GR 3rd, Odermatt A: Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals. J Steroid Biochem Mol Biol 199:105605, 2020
11. Beck KR, Bächler M, Vuorinen A, Wagner S, Akram M, Griesser U, et al.: Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole. Biochem Pharmacol 130:93-103, 2017
12. Bennett MT, Sirrs S, Yeung JK, Smith CA: Hypercalcemia due to all trans retinoic acid in the treatment of acute promyelocytic leukemia potentiated by voriconazole. Leuk Lymphoma 46:1829-1831, 2005
13. Rodriguez JA, Ivancic S, Eckardt PA, Lemos-Ramirez JC, Niu J: A Case of pulmonary histoplasmosis presenting with hypercalcemia and altered mental status in a patient following allogeneic hematopoietic stem cell transplantation. Am J Case Rep 21:e919724, 2020
14. McGovern B, Garan H, Kelly E, Ruskin JN: Adverse reactions during treatment with amiodarone hydrochloride. Br Med J (Clin Res Ed) 287:175-180, 1983
15. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al.: The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 57:662-669, 1995